The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

Publications

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC

Safety-related regulatory actions for biologicals approved in the United States and the European Union.

JAMA 2008 Oct 22;300;1887-96 — 2008 Oct 22 — 1887-96

Veach SA, Franks AM, Allan MC

Severe anaphylactic reaction after repeated intermittent exposure to lepirudin.

Pharmacotherapy 2007 May;27;760-5 — 2007 May — 760-5

Cardenas GA, Deitcher SR

Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia.

Mayo Clinic proceedings 2005 Apr;80;491-3 — 2005 Apr — 491-3

Greinacher A, Lubenow N, Eichler P

Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.

Circulation 2003 Oct 28;108;2062-5 — 2003 Oct 28 — 2062-5